Global Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Market, By Type (Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)), Treatment (Antimalarial Therapy, Steroids, Cyclophosphamide, Azathioprine, Methotrexate, Benlysta, Rituximab, Others), Dosage (Solution, Injection, Others), Route of Administration (Subcutaneous, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.